B-lymphoma cell (B-NHL cell)

B-lymphoma cells represent malignant populations of B-lymphocytes that have undergone neoplastic transformation, typically characterized by uncontrolled clonal expansion within the lymphatic system [1]. These cells are the hallmark of various B-cell non-Hodgkin lymphomas (NHLs) and are often driven by genetic translocations or mutations that dysregulate growth and survival pathways, such as the B-cell receptor (BCR) signaling cascade [2]. While the cell itself is the pathological entity of the disease, therapeutic strategies focus on targeting specific proteins expressed by these cells, including surface antigens like CD20 or intracellular enzymes like Bruton's tyrosine kinase (BTK) [3]. B-lymphoma cells often develop mechanisms to evade the host immune response and resist programmed cell death, frequently through the overexpression of anti-apoptotic proteins like BCL-2 [4]. Modern pharmacological intervention involves a combination of monoclonal antibodies, small-molecule inhibitors, and cytotoxic agents designed to selectively deplete these malignant cells while sparing healthy tissue [1][3]. References: [1] StatPearls, 'B-Cell Lymphoma' (2023); [2] NCI Dictionary, 'B-cell lymphoma'; [3] Journal of Hematology & Oncology, 'Targeted therapy in B-cell lymphomas' (2020); [4] ASH Education Program, 'Targeting B-cell receptor signaling' (2019).

Other names

Malignant B-lymphocyteB-cell lymphoma cellB-NHL cellLymphoma B-cellNeoplastic B-cell

Targeting specific molecular markers on or within the cell to induce apoptosis, inhibit B-cell receptor (BCR) signaling, or trigger antibody-dependent cellular cytotoxicity (ADCC).